Next-generation metagenomic sequencing test developed at UCSF proves its effectiveness in quickly diagnosing almost any kind ...

Development of the coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets ...

1 Maresso and his team had been examining wastewater for about ... “We had the idea that maybe SARS-CoV-2 was in the ...

The risk for VTE was reduced among Military Health Systems beneficiaries who were vaccinated vs unvaccinated against COVID-19.

Booster doses of the original monovalent COVID-19 vaccine are associated with lower incidence of symptoms in health care personnel 6 weeks postinfection.

I am therefore confident that our approach should be effective not only during future outbreaks of SARS-CoV-2 variants of concern ... which could extend the field of application in the future. [1] ...

including a total of 1 219 185 individuals (adults and children) with documented SARS-CoV-2 infection and 634 201 individuals ...

Hospital and ICU admission rates within 30 days after COVID-19 infection were greater in patients with inborn errors of immunity (IEI).

Discover six exosome therapy companies developing these tiny extracellular vesicles to treat an array of diseases.